Four independent regions within 8q24 near the MYC gene are associated with risk for prostate cancer (Pca). Here, we investigated allelic imbalance (AI) at 8q24 risk variants and MYC gene DNA copy number (CN) in 27 primary Pcas. Heterozygotes were observed in 24 of 27 patients at one or more 8q24 markers and 27% of the loci exhibited AI in tumor DNA. The 8q24 risk alleles were preferentially favored in the tumors. Increased MYC gene CN was observed in 33% of tumors, and the co-existence of increased MYC gene CN with AI at risk loci was observed in 86% (Po0.004 exact binomial test) of the informative tumors. No AI was observed in tumors, which did not reveal increased MYC gene CN. Higher Gleason score was associated with tumors exhibiting AI (P ¼ 0.04) and also with increased MYC gene CN (P ¼ 0.02). Our results suggest that AI at 8q24 and increased MYC gene CN may both be related to high Gleason score in Pca. Our findings also suggest that these two somatic alterations may be due to the same preferential chromosomal duplication event during prostate tumorigenesis.
Introduction
At least four independent susceptibility loci for prostate cancer (Pca) risk have been identified on chromosome 8q24.21 among diverse ethnic populations. [1] [2] [3] [4] [5] [6] Three of these regions are contiguous and independent and are denoted as region 1 (Build 36, 128.54-128.62 Mb), region 2 (128.14-128.28 Mb), and region 3 (128.47-128.54 Mb). Common single-nucleotide polymorphisms (SNPs) within these regions that have been consistently replicated in Pca risk are rs1447295 (region 1), rs16901979 (region 2), and rs6983267 (region 3), respectively. [1] [2] [3] [4] [5] [6] The three riskassociated regions cluster within a 600-kb sequence that contains no known genes. In an earlier case-control study of African Americans (AAs), we also confirmed these findings on 8q24.21 and further identified a novel independent locus (denoted as region 4) around SNP rs7008482 located on 8q24. 13, 6 which lies within the NMSCE2 gene.
The association of 8q24 SNPs with Pca risk has also been confirmed by many other follow-up studies. [7] [8] [9] Interestingly, SNPs within 8q24 are not only associated with Pca risk, but also with the risk of colorectal, breast, bladder, and kidney cancer. [9] [10] [11] [12] [13] [14] The consistent finding of association between 8q24 SNPs and elevated risk of human cancers suggests that a common biological mechanism may contribute to development of various human cancers. However, our efforts to elucidate the molecular mechanisms that contribute to carcinogenesis have been slow, as there are no known genes in the region. The closest and strongest candidate gene is the MYC oncogene, which is approximately 200 kb from risk region 1. The established function of the MYC oncogene in various human cancers makes it the most promising candidate susceptibility gene in the 8q24 region. Recently, SNP rs9642880, 30 kb upstream of MYC, was shown to be strongly associated with bladder cancer risk. 12 However, genetic variation in the MYC gene has been experimentally excluded as risk factors for prostate or colon cancer risk. [1] [2] [3] [4] [10] [11] It is unclear if the underlying 8q24 risk alleles interact or influence the MYC gene during prostatic carcinogenesis, yet it is known that MYC gene amplification and overexpression has been associated with human Pca development. [15] [16] [17] [18] [19] [20] Frequent MYC amplification has been reported in high-grade prostatic intraepithelial neoplasia, primary Pca, and metastases, [15] [16] [17] [18] [19] [20] and both MYC mRNA transcripts and nuclear MYC protein are elevated in some Pcas. 20 Furthermore, nuclear MYC protein is commonly found to be overexpressed in luminal cells of prostatic intraepithelial neoplasia, most primary tumors, and metastatic disease. However, MYC protein expression is not correlated with 8q24 amplification, suggesting alternative mechanisms for MYC overexpression. 20 Recently, allelic imbalance (AI) of the G allele of the 8q24 SNP rs6983267 was reported in colorectal tumors, suggesting that germline genetic defect at this locus may have a function in the somatic evolution of human colorectal cancer.
14 However, similar findings have not been reported in Pca. In this study, we investigated the relationship between MYC gene amplification and AI of 8q24 risk alleles and Pca clinical features. AI status was examined at SNPs in the four independent 8q24 regions associated with Pca risk in primary prostate tumor tissues and paired normal tissues collected from AA and European American (EA) patients. In addition, we also measured MYC gene DNA copy number (CN) and AI status within the MYC gene-coding region.
Materials and methods

Study subjects and DNA extraction
The study population originally consisted of 18 AA patients and 13 EA patients with Pca. However, three AA samples and one EA sample were excluded in this study because of the lack of matched normal tissue samples. Surgical specimens collected at the Johns Hopkins Hospital between 1993 and 2007 were selected for processing because of relative homogeneity of nodules of both tumor tissue and benign tissue in the specimen. The tissue, frozen at the time of surgery, was sectioned on a cryostat and microscopically trimmed to isolate benign tissue from tumor tissue. Confirmatory hematoxylin and eosin sections as well as slides for immunohistochemical staining were taken both before and after the sections that would be kept for processing. Genomic DNA was extracted from the frozen tissue sections using Trizol reagent. Processing of the samples was performed in a manner blinded to ethnic origin and malignant composition.
Analysis of sample composition
Pathologic review was performed for each representative section of tumor and normal tissue before and after trimming of the surgical specimen was performed. Where hematoxylin and eosin staining alone was insufficient to properly diagnose a set of sections, immunohistochemial analysis was undertaken. An estimate of the proportion of neoplastic cells was made for each benign and tumor sample. Each tumor sample was then assigned a Gleason grade. For the tumor tissue, 69.4% of the material processed contained over 70% Pca cells with a Gleason score of 3 þ 3 or greater. AI and MYC gene CN analysis were not conducted in tumor samples containing o50% neoplastic cells on final pathologic detection in this study. Ethnicity and clinical characteristics including age at diagnosis, Gleason score, and tumor stages are listed in Table 1 .
SNP genotyping and AI analysis
Genotyping and AI assessment were carried out by PCR and direct DNA sequencing for five SNP markers at four independent risk-associated regions on 8q24 (Table 1) . Primers used for PCR amplification and DNA sequencing were synthesized by Integrated DNA Technologies (Coralville, IA, USA). All the sequences of primers are available on request. The PCR mixture in a total volume of 20 ml consisted of 20 ng genomic DNA, 1 U AmpliTaq polymerase (Perkin Elmer, Foster City, CA, USA), 10 Â PCR buffer II (Perkin Elmer), 2.0 mM MgCl 2 , 0.6 mM each dNTP, and 12 pmol of each primer. Reaction conditions included an initial melting step at 95 1C for 15 min, followed by 35 cycles of melting at 95 1C for 30 s, annealing at 60 1C for 30 s, and extending at 72 1C for 30 s. A final extension was set at 72 1C for 8 min. For DNA sequencing, PCR products were treated by using ExoSAP-IT (USB, Cleveland, OH, USA) according to the user protocol, and then sequenced by using ABI 3730XL DNA sequencers (Applied Biosystems, Foster City, CA, USA) at the Cancer Research Center DNA Sequencing Core Facility, the University of Chicago.
AI can only be identified in 'informative' cases, which carry a heterozygous genotype at a given SNP locus. AI of the five markers was scored by comparing the ratios of the allele peak heights in sequencing graphs between tumors and matched normal DNA samples as described earlier. 21 The cutoff scores, which denoted 'high' AI were 41.67 or o0.60, 21 and the ratio scores that denote 'moderate' AI were 41.25 or o0.80.
Quantitative PCR
Real-time PCR with the Mx3000P system (Stratagene, La Jolla, CA, USA) and iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) was used to quantify the number of copies of the MYC gene according to a similar protocol described earlier. 22 Briefly, a 157-bp amplicon in the exon-3 of MYC gene was amplified with primers (forward: 5 0 -TGGATCACCTT CTGCTGGA-3 0 and reverse: 5 0 -TCTGACACTGTC CAACTTGACC-3 0 ). A 149 bp amplicon in the LINE1 sequence was served as an internal control. 23 Real-time PCR for both MYC and LINE 1 was cycled 45 times at 95 1C for 20 s, 55 1C for 1 min, and 72 1C for 30 s after preheating at 95 1C for 10 min. Measurement of both amplicons was repeated three times. MYC data was normalized to that of the LINE1 sequence (R1). The MYC/ LINE1 ratio in the tumor DNA was then normalized to that of the normal tissue (R2), and the MYC gene CN in each tumor sample was calculated by doubling the R2 value. In this study, the MYC gene was considered duplicated in tumor tissue when the CN was X2.20.
MYC gene mutation screening
The coding region of the MYC gene was screened by using DNA sequencing in five selected Pca tumor samples. Primers used in PCR reaction can be available under request. PCR conditions and DNA sequencing were the same as above.
Statistical analysis
ANOVA analyses (F-test) were used to detect associations between AI status and clinical features. The exact binomial test was performed to determine the association between AI status and MYC CN. All analyses were two 8q24 AI and MYC CN in prostate cancer H Chen et al sided. Analyses were performed for all subjects combined and separately for EA and AA ancestry. Table 1 shows the genotypes and AI status of the five 8q24 SNP markers in our 27 AA and EA prostate tumor/ normal DNA pairs. Forty-nine heterozygous genotypes were identified and 13 of them (27%) exhibited AI, including 7 high and 6 moderate ( Table 1) . Three subjects (cases 9, 14, and 17) were homozygous at all the five markers and could not be analyzed for AI.
Results
8q24 AI analyses
For the region 3 SNP rs6983267, a total of seven heterozygous cases (three AA and four EA patients) were observed, and two patients (the AA case 5 and the EA case 16) exhibited high AI at rs6983267 with AI scores of 1.72 and 1.99, respectively (Table 1 ; Figures 1a and b) . It should be noted that in both these two tumor tissues, the rs6983267 risk allele 'G' was favored (Figure 1a and b) . Owing to the low heterozygosity of rs6983267 in the African descent population, we typed another region 3 SNP rs7014346, which is about 11 kb telomic to rs6983267 and 60 kb away to rs1447295 (region 1). SNP rs7014346, which is in the strong linkage disequilibrium with rs6983267, exhibits higher heterozygosity among both the European and African populations and is associated with colorectal cancer risk. 14 We observed 12 heterozygous patients for the rs7014346 A/G polymorphism ( Table 1) . One AA patient (case 12) showed high AI at rs7014346 (AI score 1.70) and another AA patient (case 1) had moderate AI at rs7014346 with the risk allele A favored in tumor cells (Figure 1h) .
High AI was also seen at the other three 8q24 regions. At rs1447295 in region 1, the closest risk-associated region to the MYC gene, 30.7% (4/13) of heterozygotes were observed with AI (three significant and one moderate) (Table 1) . Notably, the risk allele A of rs1447295 was favored in all four (100%) of tumor samples with AI. At rs16901979 in region 2, moderate AI was observed in three of six AA heterozygous patients (cases 1, 4, and 6) (Table 1; Figure 1g ). Interestingly, in case 6 the rs16901979 risk allele 'A' was shown favored, but in the other two (cases 1 and 4) the wild type allele 'C' was favored.
The risk-associated SNP rs7008482, 2 Mb away from the MYC gene in region 4, is located in the intronic region of NSMCE2. The NSMCE2 gene (also named as hMMS21, NSE2) encodes a SUMO ligase, which functions in DNA repair in human cells. 24 The risk allele G of rs7008482 is very common among European and African descendents. For SNP rs7008482, an EA patient (case 21) showed high AI (AI score 1.68) (Table 1; Figure 1e ), whereas another EA patient (case 18) showed moderate AI. Of note, the risk allele rs7008482 G was found to be favored in both cases (100%).
In most informative patients, AI could be observed consistently at these informative SNP markers (Table 1) . For example, in patient 21, high AI was observed at both rs7008482 and rs1447295, and for patient 12, AI was shown to be high for rs7014346 and rs1447295 as well. In AA case 5, however, significant AI was only shown at the 8q24 AI and MYC CN in prostate cancer H Chen et al heterozygous rs6983267 (Figure 1a ), but not at SNP rs1447295 (Figure 1d ).
MYC gene CN analysis
Among these 27 tumor/normal DNAs, increased MYC gene CN (CNX2.20) was found in 9 samples (6 AA patients and 3 EA patients) by using real-time PCR ( Correlation between 8q24 SNP AI, MYC gene CN, and disease aggressiveness
The frequency of AI at the 8q24 markers was slightly higher among heterozygous loci in AAs (8/28 or 27%) than in EAs (5/21 or 24%). Among informative samples, tumor Gleason scores were higher in patients with high AI at two or more loci than in patients without AI (P ¼ 0.04). In addition, increased MYC CN was associated with higher Gleason scores (P ¼ 0.02). No associations were observed for AI or MYC gene CN and tumor stage, race, or age at diagnosis. The presence of both AI and increased MYC CN was observed in 88% of informative tumor/normal DNA pairs. MYC CN alteration was strongly associated with AI (P ¼ 0.0001). No AI was observed in informative tumor/normal pairs without MYC gene CN alteration.
Mutation detection in the MYC gene
The coding region of MYC gene was screened by DNA sequencing in five selected DNAs (cases 5, 12, 16, 18, and 21), which showed significant AI and increased MYC gene CN. No somatic mutations were identified in the MYC gene-coding region in these five prostate tumors. However, two known SNPs, rs4645959 A/G and rs4645970 A/G, were observed in patient 16 and 8q24 AI and MYC CN in prostate cancer H Chen et al patient 12, respectively, and they both displayed high AI (Figure 2a and 2b) . The SNP rs4645959, a missense variant (N26S) in MYC exon-2 with the S allele creating a PDK1 binding motif, has been shown in correlation with familial breast cancer risk. 25 However, it was the wild type rs4645959 'A' allele that was overrepresented in the prostate tumor in this study (Figure 2b ).
Discussion
In this study, we observed that high AI of 8q24 risk alleles was common (27%) in primary Pcas. Notably, the risk alleles of rs1447295 'A' (region 1), rs6983267 'G' (region 3), and rs70008482 'G' (region 4) are preferentially amplified in all Pca samples when presenting with AI. This finding suggested that these selectively favored risk alleles in prostate tumor cells could have an oncogenic function during prostate carcinogenesis. We also found that increased MYC gene CN is commonly accompanied with 8q24 allelic amplification in prostate tumor cells, indicating that the co-existence of 8q24 AI and gain of MYC gene CN might be due to the same event of 8q24 chromosomal amplification. Furthermore, we showed that both 8q24 AI and MYC gene amplification may be associated with high Gleason score (47) and possibly aggressive Pca. Similarly, earlier studies using CGH assay and/or a dual-color labeling probe of MYC gene have shown that MYC gene copies tend to only slightly increase, mostly under five or less copies. [17] [18] [19] Our study further revealed that the increased MYC gene CN is likely due to preferential amplification of a large 8q24 chromosomal fragment in Pca. Similar to our findings in Pca, a recent 8q24 CN analysis in colorectal cancers observed that a large segment of the rs6983267 G allele-bearing chromosome region is typically overrepresented three to five times in colorectal tumors. 26 Earlier studies have shown that germline variation of the JAK2 oncogene predisposes to increased risk of specific somatic mutations, suggesting that strong interactions may exist between somatic and germline changes within oncogenes. 27 Indeed, we observed frequent MYC gene amplification and AI in Pcas, suggesting that somatic MYC gene amplification in Pca might not be equally contributed from the two parent chromosomes. To test whether MYC is involved in Pca through the same mechanism as JAK2, we sequenced MYC-coding region. However, we could not detect any somatic mutations, indicating that MYC may be rarely mutated in Pca, and the interaction of germline and somatic DNA changes might not exist in the MYC oncogenes involvement in Pca. Given the small sample size, we cannot exclude the possibility that this mechanism may exist.
Our study is the first report on common AI of 8q24 risk-associated markers in Pcas. However, we acknowledge that this study has several important limitations. The sample size of prostate tumors we analyzed in this study is very small. Even though a difference in AI frequency and MYC DNA CN alteration was observed between AA and EA patients, we may not have estimated the exact rates of AI and MYC gene CN alteration, nor the significance of our findings in the AA or EA populations when genetic background is concerned. Furthermore, because of the level of homozygosity for the five 8q24 markers, three patients were 'uninformative' for AI assessment in this study, including one of our cases with the highest Gleason score. Therefore, future studies should be conducted using more informative markers in a larger number of prostate tumor samples to access AI at 8q24 risk-associated regions.
Conclusion
In this study, we reported common and preferential AI at 8q24 risk-associated regions and frequent MYC amplification in primary prostate tumors. Both 8q24 AI and MYC amplification occur simultaneously and seem to be related to aggressive Pcas; however, larger numbers of samples are needed to confirm our findings. These findings will help extend our understanding of the relevance of common genetic variation in the 8q24 region and MYC gene amplification in the etiology and pathology of Pca. 8q24 AI and MYC CN in prostate cancer H Chen et al
